Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.485
-0.095 (-6.01%)
Mar 31, 2025, 2:22 PM EDT - Market open

Company Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.

The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.

The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc.
Lucid Diagnostics logo
Country United States
Founded 2018
IPO Date Oct 14, 2021
Industry Medical Devices
Sector Healthcare
Employees 70
CEO Lishan Aklog

Contact Details

Address:
360 Madison Avenue, 25th Floor
New York, New York 10017
United States
Phone 917 813 1828
Website luciddx.com

Stock Details

Ticker Symbol LUCD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001799011
CUSIP Number 54948X109
ISIN Number US54948X1090
Employer ID 82-5488042
SIC Code 3841

Key Executives

Name Position
Dr. Lishan Aklog M.D. Chairman and Chief Executive Officer
Shaun M. O'Neill M.B.A. President and Chief Operating Officer
Dennis M. McGrath CPA Chief Financial Officer
Michael Adam Gordon General Counsel and Secretary
Dr. Sanford D. Markowitz M.D., Ph.D. Co-Founder and Strategic Advisor
Dr. Joseph Willis M.D. Co-founder and Strategic Advisor
Dr. Amitabh Chak M.D. Co-Founder and Strategic Advisor
Helen Moinova Ph.D. Co-Founder and Strategic Advisor
Dr. Brian J. deGuzman M.D. Chief Technology and Compliance Officer
Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 25, 2025 8-K Current Report
Mar 24, 2025 10-K Annual Report
Mar 5, 2025 8-K Current Report
Mar 5, 2025 424B5 Filing
Mar 4, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Feb 25, 2025 8-K Current Report
Feb 13, 2025 SCHEDULE 13G/A Filing
Jan 31, 2025 S-8 Securities to be offered to employees in employee benefit plans
Jan 31, 2025 S-8 Securities to be offered to employees in employee benefit plans